English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Encapsulating peritoneal sclerosis (EPS) is a serious problem for chronically dialysed patients [1,2]. With an overall prevalence of 2–3% in patients undergoing peritoneal dialysis (PD), it is now obvious that extended duration of PD therapy increases the incidence and severity of EPS [3]. Mortality rates in patients with EPS remain high—especially after bowel obstruction becomes an overt problem, although success with intra-abdominal surgery is no longer a far-fetched option [2,4]. Pharmacological therapeutic choices are based on anecdotal evidence alone, but a combination of prednisone and tamoxifen has been used in an attempt to reduce both the inflammatory and fibrotic changes associated with this disease [2,5]. Tamoxifen was originally used in desmoid tumours, and since then the drug has proved to be of value in other fibroproliferative disorders, such as retroperitoneal fibrosis and Dupuytren’s contracture [6]. However, tamoxifen produces oestrogenic-like effects on certain tissues, and can lead to an increased incidence of venous thromboembolism [7]. Over the last year, we treated two patients with advanced EPS, with prednisone and tamoxifen. Both developed overwhelming, and ultimately fatal, calciphylaxis. Their case reports follow, together with a discussion on the possible role of tamoxifen in initiating calciphylaxis—a condition characterized by the presence of intraluminal thrombi in small calcified blood vessels of the dermis [8]. Some precautionary measures that can be undertaken before commencing tamoxifen in patients with EPS are given. Case 1

A worrying thought—could there be a connection between encapsulating peritoneal sclerosis, tamoxifen and calciphylaxis?